DC-SCRIPT, or dendritic cell-specific transcript, is a key regulator of nuclear receptor activity that may have prognostic value in breast cancer, according to a new study published online December 14 in the Journal of the National Cancer Institute.
In this study, a team led by Gosse J. Adema, Ph.D., of the Department of Tumor Immunology, at the Radboud University Nijmegen Medical Centre, the Netherlands, and colleagues assessed the role of DC-SCRIPT as a co-regulator of nuclear receptors, including estrogen receptor (ER), progesterone receptor (PR)-B, peroxisome proliferator–activated receptor gamma, and retinoic acid receptor alpha. Prognostic value was assessed in three independent cohorts of breast cancer patients.
The researchers found that DC-SCRIPT suppressed ER- and PR-mediated transcription in a ligand-dependent fashion, whereas it enhanced the activity of the other two receptors. Quantification of DC-SCRIPT mRNA expression in the three cohorts of patients revealed that this expression is an independent prognostic factor for breast cancer patients with ER– and/or PR–positive tumors, according to the authors.
In addition, they showed that breast tumors express lower levels of DC-SCRIPT mRNA than normal breast tissue and that breast tumor cell lines do not express it.
"On the basis of these findings, we hypothesize that the antiproliferative effect of DC-SCRIPT in breast cancer cells is mediated by modulating the activity of multiple nuclear receptors," the authors write. "It will be interesting therefore to also examine DC-SCRIPT expression levels in clinical trials that have explored the effect of stimulation of the RAR/RXR and PPAR/RXR pathways on the clinical outcome in breast cancer patients."
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.